Latest News On Drug Costs

Latest KFF Health News Stories

Podcast: KHN’s ‘What The Health?’ Reading The Tea Leaves In Blue Wave’s Wake

KFF Health News Original

In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”

Fish Oil Drug Looks Heart-Healthy. Just Don’t Swallow It Hook, Line And Sinker.

KFF Health News Original

The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didn’t find the same promise for over-the-counter fish oil supplements when tested in healthy people.

Podcast: KHN’s ‘What The Health?’ Doctors, Guns And Lame Ducks

KFF Health News Original

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss how the Democrats’ takeover of the House and other results from the Nov. 6 elections might affect health care, and what Congress may have in store for the lame-duck session.

Podcast: KHN’s ‘What The Health?’ Open Enrollment And A Midterm Preview

KFF Health News Original

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Joanne Kenen of Politico discuss the start of open enrollment for individual health insurance plans for 2019 and preview what next week’s midterm elections might mean for health policy. Plus, Barbara Feder Ostrov of KHN and California Healthline talks to Julie about the latest NPR-KHN “Bill of the Month” feature.

Podcast: KHN’s ‘What The Health?’ Trump, GOP Fight Back On Health Care

KFF Health News Original

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss a flurry of proposals from the Trump administration on prices Medicare pays for drugs and the Affordable Care Act.

Podcast: KHN’s ‘What The Health?’ Republicans’ Preexisting Political Problem

KFF Health News Original

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Stephanie Armour of The Wall Street Journal and Joanne Kenen of Politico discuss how protections for people with preexisting conditions have become a top issue in the elections, Trump administration efforts to make prescription drug prices more public and the start of Medicare’s annual open-enrollment period. Plus, Rovner interviews California Attorney General Xavier Becerra.

Podcast: KHN’s ‘What The Health?’ Falling Premiums And Rising Political Tensions

KFF Health News Original

In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.

No More Secrets: Congress Bans Pharmacist ‘Gag Orders’ On Drug Prices

KFF Health News Original

Congress approved two bills last month that prohibit provisions keeping pharmacists from telling patients when they can save money by paying the cash price instead of the price negotiated by their insurance plan.

In The Battle To Control Drug Costs, Old Patent Laws Get New Life

KFF Health News Original

Health insurers and pharmacy benefit managers are exploring how two legal provisions — which have been on the books for decades — could bring down the price tags of certain prescription medications.